Parkwalk has returned to back three-dimensional imaging developer Fuel3D as the Oxford spinout continues work on a scanner than can accurately detail sub-cutaneous tumours.

The UCL spinout has priced its shares at the top of its range and secured $150m in proceeds, up from its initial target of $100m.

The Northwestern University-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.

The AI imaging technology producer has led a round that valued hospital wifi provider Helian Health at $900m.

The Nan Fung-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.

EMS-backed gene therapy developer AvroBio has secured $99.7m in an initial public offering that could potentially rise to $115m.